These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36971493)

  • 41. Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and
    Meng N; Fu F; Sun J; Feng P; Luo Y; Wu Y; Li X; Yuan J; Yang Y; Liu H; Wang Z; Wang M
    Quant Imaging Med Surg; 2022 Sep; 12(9):4474-4487. PubMed ID: 36060584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.
    Peters HA; Weiss D; Boschheidgen M; Mamlins E; Giesel FL; Fluegen G; Kirchner J; Antoch G; Jannusch K
    PLoS One; 2024; 19(7):e0307998. PubMed ID: 39074093
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
    Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
    Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
    Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
    Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
    Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
    J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?
    Yılmaz U; Yasar Z; Korkmaz E; Yalcın B; Koparal H; Ozbilek E
    Med Glas (Zenica); 2017 Aug; 14(2):204-210. PubMed ID: 28698535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.
    Ohri N; Duan F; Machtay M; Gorelick JJ; Snyder BS; Alavi A; Siegel BA; Johnson DW; Bradley JD; DeNittis A; Werner-Wasik M
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25688115
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospective comparison of
    Kirchner J; Sawicki LM; Nensa F; Schaarschmidt BM; Reis H; Ingenwerth M; Bogner S; Aigner C; Buchbender C; Umutlu L; Antoch G; Herrmann K; Heusch P
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):437-445. PubMed ID: 30074073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What
    Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
    J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.
    Tong AN; Han SR; Yan P; Gong H; Zhao H; Yao H; Wang YM
    Med Oncol; 2014 Jan; 31(1):780. PubMed ID: 24326983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
    Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
    Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.